scholarly journals Medication safety in pregnancy – Results from the MoBa study

2014 ◽  
Vol 24 (1-2) ◽  
Author(s):  
Hedvig Nordeng ◽  
Eivind Ystrom ◽  
Malin Eberhard-Gran

This article summarizes the results of several of our studies on medication safety in pregnancy based on the Norwegian Mother and Child Cohort Study (MoBa). Medications investigated include antidepressants, NSAIDs, codeine, triptans, paracetamol and certain herbals. A major advantage of these studies is that MoBa has information on prescribed medications, over-the-counter medications and herbal medications. Moreover, MoBa enables the possibility of including a disease comparison group, and long-term follow-up into childhood. The size of MoBa enables designs like the sibling-design, which offers important advantages over studies comparing unrelated individuals. The possibility of linking MoBa to nationwide registries like the NorPD and the National Patient Registry enables validation of medication exposures and childhood diagnosis. Pharmacoepidemiological studies are vital to our understanding of the safety of medications in pregnancy, but great care must be taken in the analysis and interpretation of observational data to avoid problems of confounding and bias.

2020 ◽  
Vol 48 (7) ◽  
pp. 030006052093641
Author(s):  
Haihua Xu ◽  
Pengming Sun ◽  
Rongli Xu ◽  
Lihua Wang ◽  
Yuequan Shi

Aggressive angiomyxoma is an interstitial tumour that is often misdiagnosed and is likely to recur. There have been few reported cases of angiomyxoma in pregnant women. We report a case of a woman who was previously diagnosed with a tumour in her vulva that increased in size during both of her pregnancies and spontaneously decreased postpartum. Local excision was performed and a gonadotropin-releasing hormone agonist was administered. According to a literature review, aggressive angiomyxoma is associated with good maternal and child outcomes. Caesarean section is not the delivery method of choice, but it is indicated if the tumour is preventing vaginal birth. Treatment for angiomyxoma is mainly postpartum local resection supplemented by hormone therapy. This tumour frequently recurs and patients should undergo long-term follow-up.


The Lancet ◽  
1968 ◽  
Vol 291 (7543) ◽  
pp. 603-605 ◽  
Author(s):  
D.A. Leigh ◽  
R.N. Grüneberg ◽  
W. Brumfitt

1988 ◽  
Vol 27 (1) ◽  
pp. 45-49 ◽  
Author(s):  
L. Selvaggi ◽  
G. Loverro ◽  
F.P. Schena ◽  
C. Manno ◽  
G. Cagnazzo

1985 ◽  
Vol 147 (3) ◽  
pp. 300-305 ◽  
Author(s):  
Therèsa Moyes ◽  
T. Gavin Tennent ◽  
Anthony P. Bedford

SummaryAlthough it is widely believed that behaviour modification is successful in an institutional setting, the lasting efficacy of such programmes for adolescents with acting-out and conduct problems has long been questioned. A follow-up enquiry was carried out at one and two years on adolescent patients who had been through an institutional behaviour modification programme. The results were compared with those obtained for a similar group of patients who were accepted for the programme but not admitted; significantly more of the treatment group than the comparison group had improved in terms of behavioural outcome measures, and their level of independent living was greater.


2010 ◽  
Vol 30 (2) ◽  
pp. 227-228
Author(s):  
Marco De Santis ◽  
Carmen De Luca ◽  
Ilenia Mappa ◽  
Tomasella Quattrocchi ◽  
Daniela Ricci ◽  
...  

2020 ◽  
Vol 105 (8) ◽  
pp. 2616-2624 ◽  
Author(s):  
Eleni Papakokkinou ◽  
Daniel S Olsson ◽  
Dimitrios Chantzichristos ◽  
Per Dahlqvist ◽  
Elin Segerstedt ◽  
...  

Abstract Context Whether multisystem morbidity in Cushing’s disease (CD) remains elevated during long-term remission is still undetermined. Objective To investigate comorbidities in patients with CD. Design, Setting, and Patients A retrospective, nationwide study of patients with CD identified in the Swedish National Patient Register between 1987 and 2013. Individual medical records were reviewed to verify diagnosis and remission status. Main Outcomes Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were calculated by using the Swedish general population as reference. Comorbidities were investigated during three different time periods: (i) during the 3 years before diagnosis, (ii) from diagnosis to 1 year after remission, and (iii) during long-term remission. Results We included 502 patients with confirmed CD, of whom 419 were in remission for a median of 10 (interquartile range 4 to 21) years. SIRs (95% CI) for myocardial infarction (4.4; 1.2 to 11.4), fractures (4.9; 2.7 to 8.3), and deep vein thrombosis (13.8; 3.8 to 35.3) were increased during the 3-year period before diagnosis. From diagnosis until 1 year after remission, SIRs (95% CI were increased for thromboembolism (18.3; 7.9 to 36.0), stroke (4.9; 1.3 to 12.5), and sepsis (13.6; 3.7 to 34.8). SIRs for thromboembolism (4.9; 2.6 to 8.4), stroke (3.1; 1.8 to 4.9), and sepsis (6.0; 3.1 to 10.6) remained increased during long-term remission. Conclusion Patients with CD have an increased incidence of stroke, thromboembolism, and sepsis even after remission, emphasizing the importance of early identification and management of risk factors for these comorbidities during long-term follow-up.


Sign in / Sign up

Export Citation Format

Share Document